References
- Ligthart L, de Vries B, Smith AV et al. Meta-analysis of genome-wide association for migraine in six population-based European cohorts. Eur. J. Hum. Genet.19(8), 901–907 (2011).
- Chasman DI, Schurks M, Anttila V et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat. Genet.43(7), 695–698 (2011).
- Anttila V, Stefansson H, Kallela M et al. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat. Genet.42(10), 869–873 (2010).
- Lafreniere RG, Cader MZ, Poulin JF et al. A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Nat. Med.16(10), 1157–1160 (2010).
- Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain110(3), 675–680 (2004).
- Luciani R, Carter D, Mannix L, Hemphill M, Diamond M, Cady R. Prevention of migraine during prodrome with naratriptan. Cephalalgia20(2), 122–126 (2000).
- Waelkens J. Domperidone in the prevention of complete classical migraine. Br. Med. J. (Clin. Res. Ed.)284(6320), 944 (1982).
- Waelkens J. Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia4(2), 85–90 (1984).
- Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol.3(8), 475–483 (2004).
- Trucco M, Meineri P, Ruiz L. Preliminary results of a withdrawal and detoxification therapeutic regimen in patients with probable chronic migraine and probable medication overuse headache. J. Headache Pain6(4), 334–337 (2005).
- Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia27(7), 814–823 (2007).
- Diener HC, Dodick DW, Aurora SK et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia30(7), 804–814 (2010).
- Aurora SK, Dodick DW, Turkel CC et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia30(7), 793–803 (2010).